For decades the management of atherosclerotic cardiovascular disease using chelation therapy (NaEDTA) was denigrated by the conventional medical community.
The Trial to Assess Chelation Therapy (TACT Study) was a $31 million dollar study funded by the National Institutes of Health. This study proved that chelation therapy improved cardiovascular function. In addition, the study found there was more improvement in the cardiovascular function of diabetic patients than non-diabetic patients and these diabetic patients continued to show improvement in their cardiovascular function after completion of the 40 NaEDTA treatments required in the study.
The NIH has funded the Phase 2 study and it is currently being performed at multiple medical centers across the United States.
Our office offers this protocol.
Our office offers the exact protocol for cardiovascular chelation used in the Trial to Assess Chelation Therapy.
These treatments utilize 3 grams of NaEDTA mixed in sterile water with the additional nutrients per the American College for the Advancement of Medicine protocol used in both trials. 40 treatments are given weekly over three hours in the office using a 24 gauge angiocatheter in a peripheral vein.